Leronlimab Regulator List (a work in progress) =

New Post Public Reply Private Reply Replies (6) Message Board
ohm20 chazzledazzle #144437
9,054
Leronlimab Regulator List (a work in progress)

[+] = upregulation
[-] = downregulation

a-SMA [-],
a1-antitrypsin [+],
ADA2 (CCL5 migration to site of injury) [-],
AKT (via blockade of CCL4)[-], AMPK [+],
arachidonic acid (upregulated by CCL2, CCL3, CCL4, CCL5, CCL7 [-],
CCL8)[-],
ARG1 [-],
ASC proteins (via NLRP3 downreg)[-],
ATP (via CCL5 downreg) [-,]
b-arrestin [-],
BACH2 (via decrease of inflammatory TREG reaponse) [+],
Bcl-2 [-],
BDNF [+],
bradykinin[-],
beta- catenin (via downreg CCL5/CCL2) [-],
bFGF (-),
BTK (via SYK) [-],
caspase-1 (via NLRP3/ASC downreg) [-],
capase-3 [-],
capase 9 [-],
C5a, CA-2+[-],
Calcineurin (via downreg CA-2+[-],
cAMP (via CD38)[-],
CCL2 (MCP-1)[-],
CCL3 (MIP-1a)[-],
CCL4 (MIP-1b)[-],
CCL5 (RANTES)[-],
CCL7 (MCP-3)[-],
CCL8 (MCP-2)[-],
CCL11(Eotaxin-1)(low binding affinity) (high binding of CCR3)[-]
CCL13 (MCP-4)[-],
CCL14 (HCC-1)[-],
CCL16 (HCC-4)[-],
CCL18 [-],
CCL20 (LARC MIP3A)(not a CCR5 ligand) (via NF-kB downreg)[-],
CCR1 (via TNF-a and IL-4) [-],
CD25 (aka p55)(IL-2 receptor) [-],
CD69 [+],
CDK2 (via CCL5 downreg) [-],
CDK4 (via CCL5 downreg) [-],
CDK6 (via CCL5 downreg) [-],
CREB [+],
CTLA-4 (via IFN-a downreg)[-],
CX3CL1 (fractalkine) (NF-kB /TNF-a downregulation)[-],
CXCL1 [-],
CXCL8 [-],
CXCR4 (via downreg IL-17a, cyclin D1 (via CCL5 downreg) [-],
cyclin E (via CCL5 downreg) [-],
cytochrome c (via CCL5 downreg)[-],
DNMT1 (vis downreg of STAT3)[-],
ECM [-],
EGF/EGFR (in cancer via downreg fibroblasts, downreg GRP78) [-],
eIF2a (via PKR downreg) [-],
eIF4E [-],
EN-RAGE [-],
Erk 1 and 2[-],
FAK (via CCL5) [-],
FLNa, FOXP3 (downregulation of PKB/Akt pathway)[+],
GLP-1 [+],
GLUT-1 (via CCL5 downreg) [-],
GM-CSF (CSF2)[-],
GPR75 (increased binding of CCL5 to GPR75 due to CCR5 blockade) [effect is downreg CA2[+],
GRP78 (via M2 to M1 machrophage switch, via PI3K/AKT pathway downreg) [-],
Gsdmd [-] ,
inositol monophosphate (IP-1) IP-1 implicated in bi-polar disorder)), HbA1c (correlated with CCL5), HDL (high density lipoprotein) [+],
HGF, HIF-1a (via STAT3 downreg)[-],
HIF-2a (via NF-kb downreg)[-],
ICAM-1(intercellular adhesion molecule-)[-],
IDO (via IFN-y downreg) [-],
IFN-a (via downreg GM-CSF) [-],
IFNy (BACH2 upregulation)[-],
IL-1b (via caspase-1 downreg)[-],
IL-1Ra [+],
IL-2 [-],
IL-4 (-),
IL-5, IL-6 (via CCL5) [-],
IL-8 [-],
IL-10 [?],
IL-13 [-],
IL-16 [-],
IL-17a (via upregulation of CD69 and subsequent downregulation of TH17 cells)[-],
IL-18 (via caspase-1 downreg)[-],
IL-33, IL-36 (via TNF-a and ILF downreg)[-],
Jak 1, 2 and 3[-],
LDL (low density lipoprotein)[-],
LFA-1(lymphocyte function–associated antigen-1) [-],
macrophage polarization M2 to M1 shift, MapK (p38 MAPK)[-],
MDSC (via downreg CCL5) [-],
MEK [-],
miR21 (via downreg TFNa) [-],
MMP-1 [-],
MMP-2 (via CCL3 downreg)[-],
MMP-3, MMP-9 (CCL5/PLC pathway) [-],
MMP-12 [-],
MMP-13, mTORc1[-],
N-GSDMD [-],
NETosis[-],
neuropilin-1[-],
NF-H (neurofilament heavy) [+],
NF-kb (via PI3K/AKT downreg) [-],
NFAT (via CA2+ downreg) [-],
NLRP1 [-]
NLRP3 (via IL-36, ATP, ROS downreg) [-],
NOS (nitric oxide synthase) (via downreg NF-kb, MAPK) [-],
NO (nitric oxide) (via downreg NOS) [-],
Nox1 (via CCL5) [-],
p21 (tumor suppressor) (via downreg of PI3K/AKT)[+],
p27 (tumor suppressor) [+],
p50 (via NF-kb downreg) [-],
p53 (via downreg of NF-kb) [+],
p55 (aka CD25) [-],
p-CREB [+],
PCNA [-],
PDK1 (via PI3K)[-]
PD-L1(via downreg Nf-kb/MapK/JAK2) [-],
PDGF-B (upreg from ADA2) [-],
PI3k (via blocking CCL4 activation) [-],
PKA-Ca [+],
PKB/AT (CCL3,CCL5 blockade)[-],
PKC [protein kinase C] [via CA2+ downreg][-],
PKR (via TNF-a downreg) -[-],
PLA2 (via CCL2, CCL3, CCL5, CCL7, TNF-a, IL-1b, IFNy, GM-CSF downreg) [-],
PLC (CCL5 blockade)[-],
PPARy [+],
Prostaglandin D2 (formed from arachidonic acid) [-],
Pyk2 (via RAFTK) [-],
RAFTK (downreg of bradykinin, CCL5) [-],
RAGE [-],
RAS (via downreg Src) [-],
Reg3a [-],
ROS (via CCL5)[-],
S100A4 (via downreg of CCL5) [-],
SCG3 (Secretogranin III)(via downreg CA2+)[-],
sFas (via Nf-kB)[-],
SHP1[-],
SHP2[-],
SOCS3 [-],
SORT1 (neurotensin receptor-3) (MAP and PI3K dependent) [-],
SRC (via downregulation of Pyk2) [-],
SREBP-1a [-],
SREBP-2 [-],
STAT3 [-],
STAT4 (feedback loop, also increases CCR5) [-],
STAT5 [-],
SYK (via CCL4) [-],
TGF-b [-],
TIMP-1 [-],
TIMP-2 [-],
TIMP-3 [-],
TNF-a (via IL-10, MEK downreg)[-],
TNFR2 [-],
TFN-y, TGF-b) [-]
TNFSF14, TRPM4 (via CA-2+ downreg) [-],
TSC2 (via AKT downreg) [+],
TSLP (thymic stromal lymphopoietin) (via IL-1b, IL-4, IL-13, TNF-a downreg)[-],
VCAM-1 (via TNF-a, IL-1 downreg) [-],
VEGF [-],
ZAP70 (via CCL5) [-]

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

HANGCHA's AI-Fork Revolution: Bold Steps to 2030

Updated Category News Views 44

Forklifts and the Future: A Fork in the Road for HANGCHA There's a movement happening, folks, and I don't mean in the usual stock ticker shift way. We're talking forklifts here—AI-powered, no less. HANGCHA Group, a name that may or may not roll off the tongue but sure makes waves in manufacturing, just held its 4th Global Dealers Conference in Hangzhou, China. If you're...

Continue Reading
GrayMar’s Strategic Southeast Boost Could Reshape Market

Updated Category News Views 34

GrayMar’s Big Southeast Step Alright, let’s face it—when a company like GrayMar Environmental Services decides to go on a shopping spree, it’s a signal worth heeding, especially if they’ve got their eyes on expanding their empire across the Southeast. This time, it’s not just another map pin but a strategic play with heft. GrayMar’s picked up six locations...

Continue Reading
Jing'an District Drives Bold Investments at 2026 CIIE

Updated Category News Views 106

Jing'an's Strategic Moves at 2026 CIIE When you hear "Shanghai," you probably think bright lights, bustling streets, and a city that never sleeps. Now narrow that down even further and you get Jing'an District—a place that's climbing the ladder not just in glitz, but in strategic moves that matter. This year, during the China International Import Expo (CIIE), Jing'an...

Continue Reading
CREB Unlocks 8.50% APY Bonds for IRA Investors

Updated Category News Views 27

CRET Broadens the Path to Fixed-Income Security If you're the type who gets a rash just thinking about stock market jitters, pay attention: Compound Real Estate Bonds (CREB) has cracked the door open a bit wider for your retirement peace of mind. They've teamed up with Equity Trust to offer their rock-solid 8.50% APY bonds through self-directed IRAs. That's right—these...

Continue Reading
Munters Updates Financial Targets Amid Growth Plans

Updated Category News Views 102

Munters' Bold New Targets and Strategic Moves Ever feel like you're on a constant treadmill chasing numbers? Munters Group knows the feeling. Over in Stockholm, they've just laid out fresh strategies at their Capital Markets Day—not just any pie-in-the-sky type goals, but heavy hitters that are setting the tone for their future. CEO Stefan Aspman is all geared up,...

Continue Reading
Legal Titans Join Las Vegas Economic Board: Strategic Moves

Updated Category News Views 6

Legal Minds Stepping into Economic Turf in Las Vegas Out in the shimmering lights of Las Vegas, there's more than blackjack tables causing a stir. Joel Tasca from Greenberg Traurig, a law giant, now sits on the board of the Las Vegas Regional Economic Partnership (LVREP), marking a notable shift in local economic strategizing. Meanwhile, seasoned attorney Michael Bonner...

Continue Reading
Minerva Foods' Profit Struggles Despite Revenue Growth

Updated Category News Views 5

Setting the Stage: Minerva Foods' Latest Report Walking through the jungle of financial statements, few things are clear-cut. Minerva Foods handed out its latest report, stirring both optimism and concern among the suits at the table. Here's the brass tacks of it: a 9.5% boost in net revenue drumming up R$56.2 billion over twelve months. Sounds solid, huh? Yet, lurking...

Continue Reading
Yeastar 2026 Summit: AI, Growth, and Global Vision

Updated Category News Views 114

Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...

Continue Reading
TruGreen Boosts Military Discount, Joins 'Military Makeover'

Updated Category News Views 87

Lawn Care with a Heart Look, a lot of us grumble about mowing the grass, but TruGreen's turning lawn care into something with a little more meaning. This Veterans Day, they're not just about keeping those blades of grass in check. No, they're honoring the folks who've served this country. Their military discount just doubled from 10% to 20% through the end of November....

Continue Reading
CGI Shines with Strong Q4, Announces Dividend Hike

Updated Category News Views 57

CGI Records Impressive Fourth Quarter Growth Well, CGI's got reason to strut its stuff this time around. Clocked in with a fourth-quarter revenue of $4.15 billion - that's a nice 3.3% bump up year-over-year, if you leave the currency noise out of it, it's about 2.5%. The real kicker? Net earnings shot up 20.8%. In a world where everyone’s fighting over scraps, these...

Continue Reading

Top 5 Most Recently Viewed Articles

Deadline Approaching for Five9, Inc. (FIVN) Investors to Act

Updated Category News Views 159

Urgent Attention Required for Five9, Inc. Investors Investors in Five9, Inc. are being urged to take action due to an unresolved situation regarding a potential securities fraud class action. If you believe you’ve experienced financial losses while investing in Five9, it’s vital to understand your options as new developments arise. Overview of the Situation Five9,...

Continue Reading
Celebrating Five Decades of China-EU Diplomatic Relations

Updated Category News Views 346

Understanding the Legacy of China-EU Relations In a momentous step towards diplomatic engagement, a historic relationship blossomed between China and the European Economic Community, laying the foundation for what we know today as the European Union. Although the roots of this partnership trace back to the 1970s, the journey of collaboration has significantly evolved over...

Continue Reading
HanesBrands' Upcoming Earnings Call Set for Early November 2024

Updated Category News Views 57

HanesBrands Announces Third-Quarter 2024 Earnings Call HanesBrands Inc. (NYSE: HBI) is gearing up for its highly anticipated third-quarter 2024 investor conference call. Scheduled for 8:30 a.m. ET on Thursday, the 7th of November, this call comes in anticipation of releasing crucial financial results for the quarter ending September 28, 2024. Preparing for the Conference...

Continue Reading
Kelly Services Set to Discuss Q3 2024 Results in Upcoming Call

Updated Category News Views 80

Kelly Services to Host Q3 2024 Conference Call Kelly Services, a prominent global player in talent solutions, is gearing up to announce its third-quarter earnings. The announcement is set to be made prior to the market opening on an upcoming Thursday. Following this, a detailed financial presentation will be available on the company’s Investor Relations webpage. The...

Continue Reading
Prime Medicine Collaborates with Bristol Myers Squibb for Innovative T-Cell Therapies

Updated Category News Views 288

Prime Medicine, Inc. (Nasdaq: PRME) struck gold back in 2024 when it locked arms with Bristol Myers Squibb in a partnership poised to reshape therapeutic options for diseases through advanced ex vivo T-cell therapies. This ain't just another collaboration; it's a serious play that could send ripples across the biotech landscape. Financial Breakdown: Upfront Cash and...

Continue Reading